Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma
This is an open-label, phase Ib study evaluating the combination treatment of sintilimab and linperlisib in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (NKTCL).
Extranodal Natural Killer/T Cell Lymphoma
DRUG: Sintilimab and Linperlisib Combination Treatment
DLT, Dose-limiting toxicity, Cycle 1 (21 days)|RP2D, Phase II Recommended Dose, Cycle 1 (21 days)
Objective response rate (ORR), To investigate the antitumor efficacy, Up to 24 weeks|AE and SAE, Number of participants with adverse events (AE) and severe adverse events (SAE), Up to 24 weeks|2-year Progression-free survival(PFS), To investigate the antitumor efficacy, Defined as the proportion of patients without disease progresion, treatment discontinuation, or death for any reason within 24 months of enrollment|2-year Overall survival(OS), To investigate the antitumor efficacy, Defined as the proportion of patients without disease progresion, treatment discontinuation, or death for any reason within 24 months of enrollment
This is an open-label, phase Ib study evaluating the combination treatment of sintilimab and linperlisib in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (NKTCL).